Precigen (PGEN) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	PRECIGEN, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PGEN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		171,014,250
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 37,840	$ 65,793
Short-term investments	111,332	9,260
Receivables
Trade, less allowance for credit losses of $5,725 and $5,201 as of March 31, 2020 and December 31, 2019, respectively	19,376	20,650
Related parties, less allowance for credit losses of $2,312 as of March 31, 2020 and December 31, 2019	252	600
Other	351	4,978
Inventory	14,636	16,097
Prepaid expenses and other	5,596	6,444
Current assets held for sale	0	110,821
Total current assets	189,383	234,643
Property, plant and equipment, net	59,627	60,969
Intangible assets, net	65,489	68,346
Goodwill	63,703	63,754
Investments in affiliates	1,108	1,461
Right-of-use assets	24,036	25,228
Other assets	1,326	1,362
Total assets	404,672	455,763
Current liabilities
Accounts payable	4,777	5,917
Accrued compensation and benefits	7,209	14,091
Other accrued liabilities	9,972	12,049
Deferred revenue, including $0 and $877 from related parties as of March 31, 2020 and December 31, 2019, respectively	11,141	5,697
Lines of credit	1,205	1,922
Current portion of long-term debt, including $31,446 and $31,211 to related parties as of March 31, 2020 and December 31, 2019, respectively	31,886	31,670
Current portion of lease liabilities	4,308	4,182
Related party payables	139	51
Current liabilities held for sale	0	47,333
Total current liabilities	70,637	122,912
Long-term debt, net of current portion, including $25,000 to related parties as of March, 31, 2020 and December 31, 2019	188,730	186,321
Deferred revenue, net of current portion, including $31,020 and $30,182 from related parties as of March 31, 2020 and December 31, 2019, respectively	32,877	48,136
Lease liabilities, net of current portion	22,414	23,849
Deferred tax liabilities	2,785	2,834
Total liabilities	317,443	384,052
Commitments and contingencies (Note 16)
Total shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 170,656,834 shares and 163,274,880 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	0	0
Additional paid-in capital	1,797,450	1,752,048
Accumulated deficit	(1,708,867)	(1,652,869)
Accumulated other comprehensive loss	(1,354)	(27,468)
Total shareholders' equity	87,229	71,711
Total liabilities and shareholders' equity	$ 404,672	$ 455,763

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Credit losses, trade receivables	$ 5,725	$ 5,201
Current portion of deferred revenue	11,141	5,697
Long-term portion of deferred revenue	32,877	48,136
Current portion of long-term debt	31,886	31,670
Long-term debt, less current portion	$ 188,730	$ 186,321
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	170,656,834	163,274,880
Common stock, shares outstanding (in shares)	170,656,834	163,274,880
Related Parties, Aggregated
Related Party Transaction [Line Items]
Credit losses, related party receivables	$ 2,312	$ 2,312
Current portion of deferred revenue	0	877
Long-term portion of deferred revenue	31,020	30,182
Current portion of long-term debt	31,446	31,211
Long-term debt, less current portion	$ 25,000	$ 25,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues
Revenues	$ 29,838	$ 22,585
Other Expense, Net
Unrealized and realized appreciation in fair value of equity securities and preferred stock, net	(106)	70
Equity in net loss of affiliates	(389)	(1,640)
Loss from continuing operations before income taxes	(29,902)	(52,913)
Loss from discontinued operations, net of income taxes	(26,056)	(9,236)
Net loss	(55,998)	(62,136)
Net loss attributable to the noncontrolling interests	0	1,427
Net loss attributable to Precigen	(55,998)	(60,709)
Amounts Attributable to Precigen
Net loss from continuing operations attributable to Precigen	(29,942)	(51,473)
Net loss from discontinued operations attributable to Precigen	(26,056)	(9,236)
Net loss attributable to Precigen	$ (55,998)	$ (60,709)
Net Loss per Share
Net loss from continuing operations attributable to Precigen per share, basic and diluted (in dollars per share)	$ (0.19)	$ (0.34)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in dollars per share)	(0.16)	(0.06)
Net loss attributable to Precigen per share, basic and diluted (in dollars per share)	$ (0.35)	$ (0.40)
Weighted average shares outstanding, basic and diluted (in shares)	160,338,743	152,948,058
Collaboration and licensing agreements
Revenues
Revenues	$ 10,721	$ 5,971
Continuing Operations
Revenues
Revenues	29,838	22,585
Operating Expenses
Research and development	18,891	26,938
Selling, general and administrative	23,018	31,049
Total operating expenses	55,534	72,801
Operating loss	(25,696)	(50,216)
Other Expense, Net
Unrealized and realized appreciation in fair value of equity securities and preferred stock, net	0	449
Interest expense	(4,592)	(4,305)
Interest and dividend income	673	1,361
Other income, net	64	546
Total other expense, net	(3,855)	(1,949)
Equity in net loss of affiliates	(351)	(748)
Loss from continuing operations before income taxes	(29,902)	(52,913)
Income tax benefit (expense)	(40)	13
Loss from continuing operations	(29,942)	(52,900)
Continuing Operations | Collaboration and licensing agreements
Revenues
Revenues	10,721	5,971
Continuing Operations | Products
Revenues
Revenues	4,961	4,837
Operating Expenses
Cost of products and services	6,089	7,722
Continuing Operations | Services
Revenues
Revenues	13,946	11,383
Operating Expenses
Cost of products and services	7,536	7,092
Continuing Operations | Other
Revenues
Revenues	$ 210	$ 394

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Related Party Transaction [Line Items]
Revenues	$ 29,838	$ 22,585
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	10,721	5,971
Continuing Operations
Related Party Transaction [Line Items]
Revenues	29,838	22,585
Continuing Operations | Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	10,721	5,971
Continuing Operations | Collaboration and licensing agreements | Related Parties, Aggregated
Related Party Transaction [Line Items]
Revenues	$ 198	$ 4,790

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (55,998)	$ (62,136)
Other comprehensive income (loss):
Unrealized gain on investments	572	47
Gain (loss) on foreign currency translation adjustments	(1,415)	285
Release of cumulative foreign currency translation adjustments to loss from discontinued operations	26,957	0
Comprehensive loss	(29,884)	(61,804)
Comprehensive loss attributable to the noncontrolling interests	0	1,382
Comprehensive loss attributable to Precigen	$ (29,884)	$ (60,422)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands	Total	Total Precigen Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Balances (in shares) at Dec. 31, 2018			160,020,466
Balances at Dec. 31, 2018	$ 378,722	$ 362,855	$ 0	$ 1,722,012	$ (28,612)	$ (1,330,545)	$ 15,867
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	9,054	8,990		8,990			64
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares)			286,637
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	307	57		57			250
Shares issued for accrued compensation (in shares)			150,908
Shares issued for accrued compensation	1,102	1,102		1,102			0
Shares issued as payment for services (in shares)			157,405
Shares issued as payment for services	831	831		831
Shares and warrants issued in public and private offerings, net of issuance costs	6,611	0					6,611
Adjustments for noncontrolling interests	0	(384)		(384)			384
Net loss	(62,136)	(60,709)				(60,709)	(1,427)
Release of cumulative foreign currency translation adjustments to loss from discontinued operations	0
Other comprehensive income (loss)	332	287			287		45
Balances (in shares) at Mar. 31, 2019			160,615,416
Balances at Mar. 31, 2019	$ 334,823	313,029	$ 0	1,732,608	(28,325)	(1,391,254)	$ 21,794
Balances (in shares) at Dec. 31, 2019	163,274,880		163,274,880
Balances at Dec. 31, 2019		71,711	$ 0	1,752,048	(27,468)	(1,652,869)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense		4,372		4,372
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares)			668,786
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants		0		0
Shares issued for accrued compensation (in shares)			347,989
Shares issued for accrued compensation	$ 5,100			5,100
Shares issued as payment for services (in shares)			392,483
Shares issued as payment for services		930		930
Shares issued in private placement (in shares)			5,972,696
Shares and warrants issued in public and private offerings, net of issuance costs		35,000		35,000
Net loss	(55,998)	(55,998)				(55,998)
Release of cumulative foreign currency translation adjustments to loss from discontinued operations	$ 26,957	26,957			26,957
Other comprehensive income (loss)		(843)			(843)
Balances (in shares) at Mar. 31, 2020	170,656,834		170,656,834
Balances at Mar. 31, 2020		$ 87,229	$ 0	$ 1,797,450	$ (1,354)	$ (1,708,867)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Net loss	$ (55,998)	$ (62,136)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,810	6,577
Loss on disposals of assets, net	217	493
Gain on sale of discontinued operations	672	0
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	26,957	0
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	106	(70)
Amortization of discounts on investments, net	(233)	(352)
Equity in net loss of affiliates	389	1,640
Stock-based compensation expense	4,372	9,054
Shares issued as payment for services	930	831
Provision for credit losses	523	64
Accretion of debt discount and amortization of deferred financing costs	2,517	2,213
Deferred income taxes	0	(508)
Other noncash items	239	235
Receivables:
Trade	438	1,306
Related parties	25	1,584
Other	1,736	642
Inventory	1,202	1,381
Prepaid expenses and other	927	(322)
Other assets	7	13
Accounts payable	(917)	(1,237)
Accrued compensation and benefits	(1,941)	(1,788)
Other accrued liabilities	(2,974)	(6,129)
Deferred revenue	(10,437)	1,330
Lease liabilities	(53)	29
Related party payables	87	1,916
Net cash used in operating activities	(27,743)	(43,234)
Cash flows from investing activities
Purchases of investments	(119,267)	0
Sales and maturities of investments	18,000	45,000
Proceeds from sales of equity securities	0	418
Investments in affiliates	0	(370)
Purchases of property, plant and equipment	(3,152)	(11,523)
Proceeds from sale of assets	684	67
Proceeds from sale of discontinued operations, net of cash sold	64,240	0
Proceeds from repayment of notes receivable	2,942	0
Net cash provided by (used in) investing activities	(36,553)	33,592
Cash flows from financing activities
Proceeds from issuance of shares in a private placement	35,000	0
Proceeds from issuance of shares and warrants in public offering, net of issuance costs	0	6,611
Advances from lines of credit	8,718	1,408
Repayments of advances from lines of credit	(9,435)	(1,597)
Proceeds from long-term debt, net of issuance costs	0	376
Payments of long-term debt	(132)	(178)
Proceeds from stock option and warrant exercises	0	307
Net cash provided by financing activities	34,151	6,927
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(39)	(504)
Net decrease in cash, cash equivalents, and restricted cash	(30,184)	(3,219)
Cash, cash equivalents, and restricted cash
Beginning of period	68,434	110,182
End of period	38,250	106,963
Supplemental disclosure of cash flow information
Cash paid during the period for interest	3,568	77
Cash paid during the period for income taxes	40	30
Significant noncash activities
Accrued compensation paid in equity awards	5,100	1,102
Purchases of property and equipment included in accounts payable and other accrued liabilities	369	2,531
Cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash	$ 38,250	$ 106,963

Organization

Organization	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland. Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium. Exemplar Genetics, LLC, doing business as Precigen Exemplar, ("Exemplar") is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa. Trans Ova Genetics, L.C. ("Trans Ova"), and Progentus, L.C. ("Progentus"), providers of reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, New York, Oklahoma, Texas, and Washington. Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"), with primary operations in California. MBP Titan's proprietary methane bioconversion platform is designed to turn natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. See Note 2 for further discussion. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Through April 8, 2019, Precigen consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Precigen no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Precigen deconsolidated AquaBounty. After deconsolidating the entity in April 2019, Precigen held its AquaBounty equity securities, which it accounted for using the fair value option, until October 2019 when the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security, LLC ("Third Security"), a related party. On January 31, 2020, Precigen completed the sale of the majority of its bioengineering assets and operations to an affiliate of Third Security, which are presented as discontinued operations for all periods presented. See Notes 3 and 13 for further discussion. Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company."

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of March 31, 2020 and results of operations and cash flows for the interim periods ended March 31, 2020 and 2019 . The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2020 , or for any other future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 . The accompanying condensed consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. Liquidity Management believes that existing liquid assets as of March 31, 2020 will allow the Company to continue its operations for at least a year from the issuance date of these condensed consolidated financial statements. These condensed consolidated financial statements are presented in United States dollars and are prepared under U.S. GAAP. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its and its collaborators' product candidates. Additionally, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the three months ended March 31, 2020 , the Company incurred a net loss attributable to Precigen of $55,998 and, as of March 31, 2020 , has an accumulated deficit of $1,708,867 . Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, reduce uses of cash for operating and investing activities for non-healthcare businesses, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations and, ultimately, attain profitable operations. Risks and Uncertainties In March 2020, the World Health Organization declared the novel strain of coronavirus, now known as COVID-19, a pandemic. COVID-19 has and continues to have an extensive impact on the global health and economic environments. Commencing in the second half of March, the Company's healthcare business began to experience delays to certain of its clinical trials as a result of COVID-19. For example, starting in March, ActoBio temporarily suspended the Phase 1b/2a cohort for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, its employees, and contractors. Additionally, from April to May 2020, enrollment of new patients in the Company's PRGN-3005 Phase 1 trial was temporarily suspended, due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle instituted in light of the COVID-19 pandemic. Neither of these delays was related to safety issues in the studies, and recruitment has resumed in the Company's PRGN-3005 trial. In April 2020, as a result of market uncertainty driven by the COVID-19 pandemic and the current state of the energy sector, the Company began the process of temporarily shutting down MBP Titan operations and assessing the appropriate next steps with respect to the future of MBP Titan. The Company is closely monitoring the impact of COVID-19 on these and other aspects of its business, including Trans Ova and Exemplar. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance for the balance of 2020 and beyond cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill, long-lived assets, and additional credit losses. Equity Method Investments The Company accounts for its investments in each of its JVs and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying condensed consolidated balance sheets. See additional discussion related to certain of the Company's JVs in Note 4 . Variable Interest Entities As of March 31, 2020 and December 31, 2019 , the Company determined that certain of its collaborators and JVs, as well as Harvest, were variable interest entities ("VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of March 31, 2020 and December 31, 2019 were $1,108 and $1,461 , respectively, which represents the Company's maximum risk of loss related to the identified VIEs. See Note 4 for discussion of the Company's future funding commitments for the significant JVs. Accounts Receivable Effective January 1, 2020, the Company applies Financial Accounting Standards Board ("FASB") Accounting Standard Update ("ASU") 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including trade receivables. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance. The Company is exposed to credit losses primarily through sales of products and services by Trans Ova in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted. Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available. The following table shows the activity in the allowance for credit losses for the three months ended March 31, 2020 : Balance at December 31, 2019 $ 7,513 Charged to operating expenses 523 Write offs of accounts receivable, net of recoveries 1 Balance at March 31, 2020 $ 8,037 Segment Information The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. As of March 31, 2020 , the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) MBP Titan, (iv) Trans Ova, and (v) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, MBP Titan, and Trans Ova. See Note 19 for a description of the Human Biotherapeutics division. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to multiple reportable segments. See Note 19 for further discussion of the Company's segments. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis and there was no material impact to the accompanying consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This ASU is intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's bioengineering assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities held in Oragenics, Inc. ("Oragenics") and SH Parent, Inc. that were directly related to the subsidiaries sold: • Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc. (collectively referred herein as "Okanagan"); • Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which is a pioneering company in biological insect solutions (referred to herein as "Oxitec"); • ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds ("Fine Chemicals"); and • Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations which were previously an operating division within Precigen ("AgBio"). Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions". The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represented a strategic shift of the Company towards the Company becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and operations related to the Transactions are reclassified and presented as discontinued operations in the accompanying condensed consolidated financial statements for all periods. Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $26,957 were released to earnings and included in loss from discontinued operations. See further discussion below. The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows: TS Biotechnology Sale EnviroFlight Sale Total Assets Cash and cash equivalents $ 2,223 $ — $ 2,223 Other current assets 9,698 — 9,698 Property, plant and equipment, net 51,975 — 51,975 Intangible assets, net 20,891 4,383 25,274 Investments in affiliates — 7,817 7,817 Right-of-use assets 13,622 — 13,622 Other noncurrent assets 212 — 212 Total assets held for sale $ 98,621 $ 12,200 $ 110,821 Liabilities Deferred revenue, current (1) $ 8,723 $ — $ 8,723 Operating lease liabilities, current 2,459 — 2,459 Other current liabilities 3,058 41 3,099 Deferred revenue, net of current portion (2) 19,410 — 19,410 Operating lease liabilities, net of current portion 12,623 — 12,623 Other long-term liabilities 1,019 — 1,019 Total liabilities held for sale $ 47,292 $ 41 $ 47,333 (1) Includes deferred revenue, current, from related parties of $1,243 . (2) Includes deferred revenue, net of current portion, from related parties of $6,836 . The following tables present the financial results of discontinued operations: Three Months Ended March 31, 2020 TS Biotechnology Sale EnviroFlight Sale Total Revenue (1) $ 1,294 $ — $ 1,294 Operating expenses 896 — 896 Operating income 398 — 398 Gain on sale of discontinued operations 633 39 672 Loss on release of cumulative foreign currency translation adjustment (26,957 ) — (26,957 ) Other expense, net (129 ) — (129 ) Equity in net loss of affiliates — (38 ) (38 ) Loss before income taxes (26,055 ) 1 (26,054 ) Income tax expense (2 ) — (2 ) Loss from discontinued operations $ (26,057 ) $ 1 $ (26,056 ) (1) Includes revenue recognized from related parties of $436 . Three Months Ended March 31, 2019 TS Biotechnology Sale EnviroFlight Sale Total Revenue (1) $ 750 $ — $ 750 Operating expenses 9,119 118 9,237 Operating loss (8,369 ) (118 ) (8,487 ) Other expense, net (422 ) — (422 ) Equity in net loss of affiliates — (892 ) (892 ) Loss before income taxes (8,791 ) (1,010 ) (9,801 ) Income tax benefit 565 — 565 Loss from discontinued operations $ (8,226 ) $ (1,010 ) $ (9,236 ) (1) Includes the reversal of revenue recognized from related parties of $978 . The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying condensed consolidated statements of cash flows. Three Months Ended 2020 2019 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 1,233 Unrealized and realized depreciation on equity securities and preferred stock, net 106 379 Equity in net loss of EnviroFlight 38 892 Stock-based compensation expense (1,346 ) 806 Deferred income taxes — (481 ) Gain on sale of discontinued operations (672 ) — Loss on release of cumulative foreign currency translation adjustment 26,957 — Cash flows from investing activities Purchases of property, plant and equipment (382 ) (7,700 ) Also see Note 13 below. Equity Method Investments The Company accounted for its investment in EnviroFlight using the equity method of accounting. Summarized financial data for equity method investments included in discontinued operations are shown in the following tables for the periods in which the Company held the equity method investments. December 31, 2019 Current assets $ 703 Noncurrent assets 30,549 Total assets 31,252 Current liabilities 2,352 Non-current liabilities 88 Total liabilities 2,440 Net assets $ 28,812 Three Months Ended 2020 2019 Revenues $ 16 $ 94 Operating expenses 92 1,881 Operating loss (76 ) (1,787 ) Other, net — 4 Net loss $ (76 ) $ (1,783 ) Where applicable, the notes to the accompanying condensed consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations. Out-of-Period Adjustment During the three months ended March 31, 2020 , the Company recorded an out-of-period adjustment of $26,572 to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Transaction. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Transaction nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's financial position or results of operations for the three months ended March 31, 2020 or the year ended December 31, 2019.

Investments in Joint Ventures

Investments in Joint Ventures	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a JV formed to optimize and scale-up the Company's methane bioconversion platform technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50% . In addition, Precigen has committed to make capital contributions of up to $25,000 , and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000 , at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of March 31, 2020 , the Company's remaining commitment was $4,225 . Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(422) and $(423) as of March 31, 2020 and December 31, 2019 , respectively, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a JV formed to utilize the Company's methane bioconversion platform technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50% . In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000 , half of which was paid by the Company. Precigen has committed to make additional capital contributions of up to $10,000 , and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000 , at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of March 31, 2020 , the Company's remaining commitment was $10,000 . Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(433) and $(435) as of March 31, 2020 and December 31, 2019 , respectively, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II.

Collaboration and Licensing Rev

Collaboration and Licensing Revenue	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Revenue	Collaboration and Licensing Revenue The Company's collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. The Company recognizes the reimbursement payments received for research and development efforts in the period when the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if any milestones will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC Topic 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded as revenue from continuing operations in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2020 and 2019 . Three Months Ended 2020 2019 ZIOPHARM Oncology, Inc. $ 100 $ 1,166 Oragenics, Inc. 198 201 Intrexon Energy Partners, LLC — 977 Intrexon Energy Partners II, LLC — 504 Fibrocell Science, Inc. 10,363 383 Harvest start-up entities (1) — 2,723 Other 60 17 Total $ 10,721 $ 5,971 (1) For the three months ended March 31, 2019 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. Except for the agreements discussed below, there have been no significant changes to the agreements with our collaborators and licensees in the three months ended March 31, 2020 . Fibrocell Science Collaborations In October 2012, the Company entered into an ECC (the "2012 Fibrocell ECC") with Fibrocell Science, Inc. ("Fibrocell"), a then publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until the acquisition of Fibrocell by a third party as discussed in Note 17 . Pursuant to the 2012 Fibrocell ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. The 2012 Fibrocell ECC was subsequently amended in June 2013 to expand the field of use defined in the ECC agreement. In March 2020, the Company and Fibrocell terminated the 2012 Fibrocell ECC by mutual agreement ("Termination Agreement") with the parties agreeing that the two drug product candidates, FCX-007 and FCX-013, pursuant to the ECC would be treated as "Retained Products" under the terms of the 2012 Fibrocell ECC. As Retained Products, Fibrocell retains a license under the 2012 Fibrocell ECC to continue to develop and commercialize the Retained Products within the field of use of the 2012 Fibrocell ECC for so long as Fibrocell continues to pursue such development and commercialization. No further licenses to the Company's technology within the field of use are provided to Fibrocell. Royalty provisions set forth in the 2012 Fibrocell ECC remain in effect for the Retained Products. Additionally, the Termination Agreement provides for the Company to perform certain drug product manufacturing activities related to the Retained Products. The Termination Agreement was accounted for as a new contract and the remaining deferred revenue from the 2012 Fibrocell ECC will be recognized prospectively as the manufacturing activities are performed. In December 2015, the Company entered into a second ECC with Fibrocell (the "2015 Fibrocell ECC"). Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. In February 2020, the Company and Fibrocell mutually agreed to terminate the 2015 Fibrocell ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the 2015 Fibrocell ECC totaling $10,000 . Deferred Revenue Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consisted of the following: March 31, December 31, Collaboration and licensing agreements $ 40,209 $ 50,593 Prepaid product and service revenues 3,461 2,805 Other 348 435 Total $ 44,018 $ 53,833 Current portion of deferred revenue $ 11,141 $ 5,697 Long-term portion of deferred revenue 32,877 48,136 Total $ 44,018 $ 53,833 Revenue is recognized under the collaboration and licensing agreements as services are performed. Certain of the arrangements are not active while the other party evaluates the status of the project and its desired future development activities. The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of March 31, 2020 and December 31, 2019 , as well as the estimated remaining performance period as of March 31, 2020 . Average Remaining Performance Period (Years) March 31, December 31, Oragenics, Inc. 4.2 $ 2,823 $ 2,864 Intrexon Energy Partners, LLC 4.0 8,362 8,362 Intrexon Energy Partners II, LLC 4.7 12,843 12,843 Fibrocell Science, Inc. 1.0 7,359 17,697 Harvest start-up entities (1) 4.9 6,993 6,993 Other 2.5 1,829 1,834 Total $ 40,209 $ 50,593 (1) As of March 31, 2020 and December 31, 2019 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Short-term Investments

Short-term Investments	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	Short-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of March 31, 2020 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 110,489 $ 579 $ — $ 111,068 Certificates of deposit 264 — — 264 Total $ 110,753 $ 579 $ — $ 111,332 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2019 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 8,989 $ 7 $ — $ 8,996 Certificates of deposit 264 — — 264 Total $ 9,253 $ 7 $ — $ 9,260 As of March 31, 2020 , all of the available-for-sale investments were due within one year based on their contractual maturities. Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. There were no unrealized losses on the Company's debt security investments as of March 31, 2020 .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of March 31, 2020 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, Assets U.S. government debt securities $ — $ 111,068 $ — $ 111,068 Other — 264 — 264 Total $ — $ 111,332 $ — $ 111,332 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2019 : Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 8,996 $ — $ 8,996 Other — 264 — 264 Total $ — $ 9,260 $ — $ 9,260 The method used to estimate the fair value of the Level 2 short-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Liabilities The carrying values of the Company's long-term debt, excluding the 3.50% convertible senior notes due 2023 (the "Convertible Notes"), approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The calculated fair value of the Convertible Notes (Note 11 ) was approximately $96,000 and $126,000 as of March 31, 2020 and December 31, 2019 , respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying condensed consolidated balance sheets at amortized cost, which was $160,077 and $157,560 as of March 31, 2020 and December 31, 2019 , respectively. The Company's contingent consideration liabilities are measured on a recurring basis and were $585 at March 31, 2020 and December 31, 2019 . These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were no changes in the fair value of the Level 3 liabilities during the three months ended March 31, 2020 .

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: March 31, December 31, Supplies, embryos and other production materials $ 2,191 $ 2,282 Work in process 3,965 3,702 Livestock 6,601 7,553 Feed 1,879 2,560 Total inventory $ 14,636 $ 16,097

Property, Plant and Equipment,

Property, Plant and Equipment, Net	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment consist of the following: March 31, December 31, Land and land improvements $ 9,814 $ 9,814 Buildings and building improvements 11,765 11,765 Furniture and fixtures 1,385 1,315 Equipment 52,498 54,448 Leasehold improvements 12,839 12,821 Breeding stock 5,576 5,191 Computer hardware and software 9,426 9,434 Construction and other assets in progress 5,382 5,313 108,685 110,101 Less: Accumulated depreciation and amortization (49,058 ) (49,132 ) Property, plant and equipment, net $ 59,627 $ 60,969 Depreciation expense was $2,931 and $3,178 for the three months ended March 31, 2020 and 2019 , respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the three months ended March 31, 2020 are as follows: Balance at December 31, 2019 $ 63,754 Foreign currency translation adjustments (51 ) Balance at March 31, 2020 $ 63,703 The Company had $43,643 of cumulative impairment losses as of March 31, 2020 and December 31, 2019 . Intangible assets consist of the following as of March 31, 2020 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 89,363 $ (27,793 ) $ 61,570 Customer relationships 10,700 (8,658 ) 2,042 Trademarks 5,900 (4,023 ) 1,877 Total $ 105,963 $ (40,474 ) $ 65,489 Intangible assets consist of the following as of December 31, 2019 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 90,659 $ (26,619 ) $ 64,040 Customer relationships 10,700 (8,440 ) 2,260 Trademarks 5,900 (3,854 ) 2,046 Total $ 107,259 $ (38,913 ) $ 68,346 Amortization expense was $1,879 and $2,166 for the three months ended March 31, 2020 and 2019 , respectively.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Lines of Credit and Long-Term Debt	Lines of Credit and Long-Term Debt Lines of Credit Trans Ova had a $5,000 revolving line of credit with First National Bank of Omaha that matured on April 1, 2020. The line of credit bore interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% , and the actual rate was 4.54% as of March 31, 2020 . The line of credit was subsequently renewed through April 1, 2021 and, subsequent to the renewal, bears interest at the greater of the U.S. Prime Rate or 3.00% . As of March 31, 2020 , there was an outstanding balance of $1,205 . The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $3,725 as of March 31, 2020 . The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of March 31, 2020 . Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2020. The line of credit bears interest at 5.50% per annum. As of March 31, 2020 , there was no outstanding balance. Long-Term Debt Long-term debt consists of the following: March 31, December 31, Convertible debt $ 216,523 $ 213,771 Notes payable 3,976 4,089 Other 117 131 Long-term debt 220,616 217,991 Less current portion 31,886 31,670 Long-term debt, less current portion $ 188,730 $ 186,321 Convertible Debt Precigen Convertible Notes In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042 . The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023, unless earlier repurchased or converted. The Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the three months ended March 31, 2020 . On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date. If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723 , and additional paid-in capital, the equity component, in the amount of $50,235 . Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount. As of March 31, 2020 , the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $160,077 . The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02% . As of March 31, 2020 , the unamortized long-term debt discount and debt issuance costs totaled $39,923 . The components of interest expense related to the Convertible Notes were as follows: Three Months Ended 2020 2019 Cash interest expense $ 1,750 $ 1,750 Non-cash interest expense 2,517 2,213 Total interest expense $ 4,267 $ 3,963 Accrued interest of $1,750 is included in other accrued liabilities on the accompanying condensed consolidated balance sheet as of March 31, 2020 . ActoBio Convertible Notes In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest. The ActoBio Notes have a maturity date of September 6, 2020, accrue interest at 3.0% compounded annually ("accrued PIK interest"), are convertible into shares of ActoBio common stock at any time by the holder, and are automatically convertible in shares of ActoBio common stock upon the closing of certain financing events as defined in the ActoBio Notes. If the ActoBio Notes have not been converted to ActoBio common stock by the maturity date, ActoBio can pay the principal and accrued PIK interest in cash or with shares of Precigen common stock at its election. There are no embedded features that are required to be separated from the debt host and accounted for separately, so the ActoBio Notes were recorded at $30,000 . Interest expense was $235 and $225 for the three months ended March 31, 2020 and 2019 , respectively. As of March 31, 2020 , the carrying value of the ActoBio Notes, including accrued interest, was $31,446 . Precigen and PGEN Therapeutics Convertible Note In December 2018, in conjunction with the Securities Purchase, Assignment and Assumption Agreement with Ares Trading S.A. ("Ares Trading"), Precigen and PGEN Therapeutics jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note has a maturity date of June 28, 2021 and will be converted to Precigen common stock on the first trading day following maturity if not otherwise converted prior to that date. Prior to maturity, Ares Trading may convert the Merck Note, at their election, into (i) Precigen common stock at any time, (ii) Precigen common stock upon the Company's closing of qualified financing as defined in the agreement, (iii) PGEN Therapeutics equity upon PGEN Therapeutics closing a qualified financing as defined in the agreement, and (iv) PGEN Therapeutics common stock upon the closing of a qualified initial public offering ("IPO") of PGEN Therapeutics common stock. There is no stated interest rate on the Merck Note. However, in the event of a conversion upon a qualified IPO, the conversion price will be 90% of the IPO price. In the event Ares Trading elects to convert the Merck Note into PGEN Therapeutics equity, the Merck Note accrues interest at a rate of 5% per year ("PIK interest") and will be converted with the outstanding principal. The Company determined that the potential PIK interest and IPO conversion discount represented embedded derivatives requiring bifurcation from the debt host but had no significant value as of March 31, 2020 . Notes Payable Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $3,973 as of March 31, 2020 . Trans Ova pays monthly installments of $39 , which includes interest at 3.95% . The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets. Future Maturities Future maturities of long-term debt are as follows: 2020 $ 31,805 2021 25,329 2022 343 2023 200,356 2024 371 2025 385 Thereafter 1,950 Total $ 260,539

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three months ended March 31, 2020 , the Company had U.S. taxable loss of approximately $79,300 . For the three months ended March 31, 2020 , the Company recognized $40 of current foreign income tax expense from continuing operations. For the three months ended March 31, 2019 , the Company had U.S. taxable loss of approximately $91,600 and recorded no current domestic income tax benefit. For the three months ended March 31, 2019 , the Company recognized $14 of current foreign income tax expense from continuing operations. For the three months ended March 31, 2020 , the Company recorded no deferred tax benefit from continuing operations. For the three months ended March 31, 2019 , the Company recorded deferred tax benefit of $27 from continuing operations. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $2,785 , are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. As of March 31, 2020 , the Company has operating loss carryforwards for U.S. federal income tax purposes of approximately $647,500 available to offset future taxable income, including approximately $394,800 generated after 2017, U.S. capital loss carryforwards of approximately $199,700 , and federal and state research and development tax credits of approximately $10,000 , prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. Carryforwards generated prior to 2018 begin to expire in 2022, and capital loss carryforwards will expire if unutilized by 2024. As of March 31, 2020 , the Company's foreign subsidiaries have foreign loss carryforwards of approximately $71,900 , most of which do not expire.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Issuances of Precigen Common Stock Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020. Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 11 ), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within five business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Share Borrower maintains collateral in the form of cash or certain permitted non-cash collateral with a market value at least equal to the market value of the Borrowed Shares as security for the obligation of the Share Borrower to return the Borrowed Shares when required by the terms above. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Precigen did not receive any proceeds from the sale of the Borrowed Shares to the public or any lending fees from the Share Lending Agreement. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering. The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement. Issuances of AquaBounty Common Stock In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty. Components of Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows: March 31, December 31, Unrealized gain on investments $ 579 $ 7 Loss on foreign currency translation adjustments (1,933 ) (27,475 ) Total accumulated other comprehensive loss $ (1,354 ) $ (27,468 ) See Note 3 for further discussion of the release of cumulative losses on foreign currency translation adjustments upon the closing of the TS Biotechnology Sale.

Share-Based Payments

Share-Based Payments	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Payments	Share-Based Payments The Company measures the fair value of stock options and restricted stock units ("RSUs") issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the condensed consolidated statements of operations are presented below: Three Months Ended 2020 2019 Cost of products $ 4 $ 8 Cost of services 29 65 Research and development 589 1,341 Selling, general and administrative 5,096 6,834 Discontinued operations (1,346 ) 806 Total $ 4,372 $ 9,054 Precigen Stock Option Plans In April 2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share-based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of March 31, 2020 , there were 244,231 stock options outstanding under the 2008 Plan. Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of March 31, 2020 , there were 25,000,000 shares authorized for issuance under the 2013 Plan, of which 12,052,124 stock options and 2,891,634 RSUs were outstanding and 3,301,269 shares were available for grant. In March 2020, Precigen's board of directors approved, subject to shareholder approval at Precigen's annual meeting in June 2020, an increase of 2,000,000 shares of common stock to be reserved for issuance under the 2013 Plan. In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of March 31, 2020 , there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 770,592 stock options and 497,512 RSUs were outstanding and 2,582,279 shares were available for grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2019 9,022,282 $ 21.94 6.10 Granted 5,280,592 10.44 Forfeited (641,750 ) (18.13 ) Expired (594,177 ) (25.40 ) Balances at March 31, 2020 13,066,947 17.33 7.01 Exercisable at March 31, 2020 6,905,395 21.86 4.92 RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2019 1,781,982 $ 8.71 1.24 Granted 2,952,917 3.07 Vested (1,016,775 ) (6.16 ) Forfeited (328,978 ) (8.45 ) Balances at March 31, 2020 3,389,146 4.59 0.69 Precigen currently uses authorized and unissued shares to satisfy share award exercises. The Company's Executive Chairman ("Executive Chairman"), who previously served as the Company's Chief Executive Officer ("CEO") until January 1, 2020, received a base salary of $200 per month payable in fully-vested shares of Precigen common stock with such shares subject to a three -year lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month through March 2019 and based on the volume weighted average of the price of Precigen common stock over the 30 day period ending on the last calendar day of each month thereafter, and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Precigen and the Executive Chairman pursuant to the terms of the 2013 Plan. The RSU Agreement expired March 31, 2020. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's condensed consolidated statements of operations and totaled $454 and $486 for the three months ended March 31, 2020 and 2019 , respectively.

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Operating Leases	Operating Leases The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. The Company's leases have remaining terms of one to ten years , some of which may include options to extend the lease and some of which may include options to terminate the lease within one year . The Company uses judgment to determine whether it is reasonably possible to extend the lease beyond the initial term or terminate before the initial term ends and the length of the possible extension or early termination. The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions. The components of lease costs from continuing operations were as follows: Three Months Ended 2020 2019 Operating lease costs $ 1,760 $ 1,841 Short-term lease costs 437 479 Variable lease costs 493 514 Lease costs $ 2,690 $ 2,834 As of March 31, 2020 , maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2020 $ 5,137 2021 7,407 2022 6,957 2023 5,799 2024 5,700 2025 3,410 Thereafter 817 Total 35,227 Present value adjustment (8,505 ) Total $ 26,722 Current portion of operating lease liabilities $ 4,308 Long-term portion of operating lease liabilities 22,414 Total $ 26,722 Other information related to operating leases in continuing operations was as follows: March 31, December 31, Weighted average remaining lease term (years) 5.02 5.24 Weighted average discount rate 10.97 % 10.96 % Three Months Ended 2020 2019 Supplemental Cash Flows Information Cash paid for operating lease liabilities $ 1,877 $ 1,835 Operating lease right-of-use assets added in exchange for new lease liabilities 25 —

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY"), alleging that Trans Ova's sale of semen-sorting products and services breached a 2004 licensing agreement and infringed on XY's patents related to semen sorting. Trans Ova counterclaimed for breach of contract, antitrust, and patent invalidity, and the matter proceeded to a jury trial in the United States District Court for the District of Colorado in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial final judgment, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with the ability to continue to practice XY's technology, subject to an ongoing royalty obligation of 12.5% of gross proceeds on Trans Ova's standard sorted semen products, plus a 2% enhancement on those products utilizing "reverse-sorted semen", or semen that is frozen before being sorted. In addition, the court assigned a $5.00 minimum royalty for a straw of sexed semen. Both parties appealed the district court's order. In May 2018, the Court of Appeals for the Federal Circuit denied Trans Ova's appeal of its claims for antitrust, breach of contract and patent invalidity (except as to one patent, for which the Federal Circuit affirmed invalidity in a separate, same-day ruling in a third-party case). The Federal Circuit remanded the district court's calculation of the ongoing royalty and instructed the district court to re-calculate the ongoing royalty in light of post-verdict economic factors. In March 2019, the district court clarified the royalty base and reset the royalty rates consistent with the Federal Circuit's opinion. In an amended final judgment, the district court increased the royalty rate on Trans Ova's standard sorted semen products to 18.75% . For the reverse-sort enhancement, however, it applied a weighted, blended royalty of 12.63% to Trans Ova's entire in vitro fertilization ("IVF") service cycle that utilizes reverse-sorted semen. The district court also changed the minimum royalty for a straw of sexed semen to $6.25 for a 2- million cell straw (prorated appropriately for straws of higher cell counts), and assigned a minimum royalty for a sexed embryo at $6.25 per embryo. The new royalty rates were made retroactive to February 2016 (the end date of the trial). Since the inception of the 2004 licensing agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the district court's April 2016 post-trial order and its March 2019 post-remand order, and has recorded these payments in cost of services in the condensed consolidated statements of operations for the respective periods. For the period from inception of the 2004 licensing agreement through the district court's April 2016 order, aggregate royalty and license payments were $3,170 , of which $2,759 had not yet been deposited by XY. In 2016, the Company recorded the expense of $4,228 , representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the district court's registry, to be held until the appeals process was complete and final judgment amounts were determined. After the appeal, the district court subsequently released the funds held in its registry to XY in January 2019. As for post-trial damages, Trans Ova continued to remit payment to XY every quarter based on the original ongoing royalty rates set by the district court, though XY refused to cash those checks. Under the district court's March 2019 post-remand order clarifying the royalty base and resetting the royalty rates, Trans Ova recalculated royalties owed from February 2016 through the first quarter of 2019, plus applicable pre- and post-judgment interest, and remitted that payment, totaling $5,801 , to XY in May 2019. In June 2019, XY deposited the $5,801 into the district court's registry while the parties resolved two separate disputes over the appropriate calculation of royalties. In the first dispute, XY filed a motion claiming over $1,000 in additional back royalties. Trans Ova contested XY's motion. On February 6, 2020, the district court denied XY's motion without prejudice, holding that XY failed to satisfy its obligation under the court's local rules to meaningfully confer with Trans Ova before filing its motion. The district court held that, should XY choose to re-file its motion, it must include a substantial certificate of conferral demonstrating that it seriously and in good faith tried to resolve its disputes with Trans Ova. In the second dispute, Trans Ova moved for partial relief from judgment after XY's last patent not expressly limited to reverse sorting expired in December 2019. Trans Ova sought an appropriate reduction in its royalty obligation in light of the fact that many of its products and services do not employ reverse sorting, whereas all of XY's remaining non-expired patents are limited to reverse sorting. On May 5, 2020, the court granted Trans Ova's motion in its entirety and issued a second amended final judgment, which substantially reduced Trans Ova's royalty obligation. The court held that, as of December 4, 2019, Trans Ova's royalty obligation on standard sorted semen products terminated. For the reverse-sort enhancement, the court held that, from December 4, 2019 through January 14, 2022, Trans Ova owes a weighted, blended royalty of 3.93% on the entire IVF service cycle. From January 15, 2022 through May 21, 2022, Trans Ova will owe XY a royalty rate of 5% on just the reverse-sort and IVF procedure components of the IVF service cycle, with no royalty being owed on the ovum pick-up and IVF drug components of the cycle. The order is subject to appeal by XY. On May 22, 2022, Trans Ova will cease owing XY any royalty for the litigated patents. In December 2016, XY filed a complaint for patent infringement, trade secret misappropriation, and various state law claims against Trans Ova in the United States District Court for the Western District of Texas in Waco, Texas. Since the claims in the 2016 complaint directly relate to the parties' other litigation, Trans Ova succeeded in transferring the case to the same Colorado district court that presided over the 2012 litigation. That court subsequently dismissed nine of the complaint's twelve counts, including all five non-patent counts and four patent counts. The court subsequently dismissed a fifth patent count after ruling that the patent was invalid, leaving only two patent counts left in the case. In February 2019, a Wisconsin district court invalidated one of the two remaining patents, which XY had asserted against another competitor. After initially appealing the Wisconsin court's invalidation of its patent, XY subsequently withdrew the appeal. In March 2019, the Colorado district court stayed the two remaining patent counts (including the one later invalidated by the Wisconsin court) and entered final judgment against XY's ten other dismissed counts. The 2016 litigation is administratively closed, pending disposition of XY's appeal to the Federal Circuit, in which XY has appealed the district court's dismissal of four of its patent causes of action. XY did not appeal the dismissal of any of the non-patent causes of action. The Federal Circuit hearing was held on March 5, 2020, and the court's decision remains pending. Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. In October 2018, the Company received a subpoena from the Division of Enforcement of the SEC informing the Company of a non-public, fact-finding investigation concerning the Company's disclosures regarding its methane bioconversion platform. The Company has produced documents to, and met with, the staff of the SEC and is voluntarily cooperating with the SEC investigation. In November 2019, the staff of the SEC informed the Company that its investigative work was largely completed. The Company and the staff of the SEC are currently in discussions, and there can be no assurance regarding the ultimate outcome of the investigation. The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including Harvest, the IEP Investors, and the IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding as of March 31, 2020 . These disagreements and disputes may result in litigation, unfavorable settlements, or concessions by the Company, adverse regulatory action, or management distraction, any of which could harm the Company's business or operations. The Company may become subject to other claims, assessments, and governmental investigations from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2020 , the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's Executive Chairman and a member of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. Through December 2019, the Company was party to a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. Under the Services Agreement, as consideration for providing these services, Third Security was entitled to a fee paid in the form of fully-vested shares of Precigen common stock that approximated $800 per month. In 2019, the number of shares of common stock was calculated based on the volume weighted average of the closing price of the Company's common stock over the 30 -day period ending on the 15th day of the calendar month when the applicable services were provided. For the three months ended March 31, 2019 , the Company accrued $2,078 for services rendered pursuant to the Services Agreement, and the shares were issued in the second quarter of 2019. Following the expiration of the Services Agreement, the Company entered into a new agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf. The total expenses incurred by the Company under these arrangements were $38 and $17 for the three months ended March 31, 2020 and 2019 , respectively. See also Note 14 regarding compensation arrangements between the Company and its Executive Chairman. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $22 for the three months ended March 31, 2020 and 2019 . See Notes 1 , 3 , and 13 regarding additional transactions with affiliates of Third Security. Transactions with ECC Parties Collaborators in which the Company holds more than a de minimis equity interest, including interests received as upfront or milestone payments through collaborations, are considered related parties. The Company held Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), a convertible note, common shares of Fibrocell, and warrants to purchase shares of Fibrocell common stock previously acquired through collaborations and other transactions. In December 2019, Fibrocell was acquired by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek"), a privately held company focused on developing medicine for rare genetic disorders. As a result, the Company received $1,280 in December 2019 for its shares of Fibrocell common stock and received a total of $3,311 in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. The $3,311 is included in other receivables on the accompanying condensed consolidated balance sheet as of December 31, 2019. Subsequent to the acquisition by Castle Creek, Fibrocell is no longer a related party.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The following table presents the computation of basic and diluted net loss per share: Three Months Ended 2020 2019 Historical net loss per share: Numerator: Net loss from continuing operations attributable to Precigen $ (29,942 ) $ (51,473 ) Net loss from discontinued operations attributable to Precigen (26,056 ) (9,236 ) Net loss attributable to Precigen $ (55,998 ) $ (60,709 ) Denominator: Weighted average shares outstanding, basic and diluted 160,338,743 152,948,058 Net loss per share: Net loss from continuing operations attributable to Precigen per share, basic and diluted $ (0.19 ) $ (0.34 ) Net loss from discontinued operations attributable to Precigen per share, basic and diluted (0.16 ) (0.06 ) Net loss attributable to Precigen per share, basic and diluted $ (0.35 ) $ (0.40 ) The following potentially dilutive securities as of March 31, 2020 and 2019 , have been excluded from the above computations of diluted weighted average shares outstanding for the three months then ended as they would have been anti-dilutive: March 31, 2020 2019 Convertible debt 31,614,643 22,025,046 Options 13,066,947 11,705,841 Restricted stock units 3,389,146 2,288,017 Warrants 133,264 133,264 Total 48,204,000 36,152,168

Segments Segments

Segments Segments	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segments	Segments Through March 31, 2019, the Company was a single operating segment. In April 2019, the Company initiated efforts to better deploy resources, realize inherent synergies, and position the Company for growth with a core focus on healthcare and initiated plans to achieve this through various corporate activities ultimately resulting in the closing of the Transactions in January 2020 (Note 3 ). Beginning in the second quarter of 2019, the Company's CODM assessed the operating performance of and allocated resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) adjustments for bonuses paid in equity awards, (vi) loss on impairment of goodwill and other long-lived assets, (vii) equity in net loss of affiliates, and (viii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. For the three months ended March 31, 2020 , the Company modified the current period definition of Segment Adjusted EBITDA to exclude adjustments recorded to reverse the difference of bonuses accrued as of December 31, 2019 compared to the value of equity awards granted, as the Company determined in March 2020 that those accrued bonuses would be paid through the grant of equity awards instead of cash. Segment Adjusted EBITDA for the three months ended March 31, 2020 was not impacted by this change. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's CODM now regularly reviews disaggregated financial information for each of the Company's operating segments. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to the newly identified reportable segments and also excludes consideration of all of the businesses included in the Transactions (Note 3 ). For the three months ended March 31, 2020 , the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) MBP Titan, (iv) Trans Ova, and (v) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the three months ended March 31, 2020 . See Note 1 for a description of PGEN Therapeutics, ActoBio, MBP Titan, and Trans Ova. The Company's Human Biotherapeutics division is an operating division within Precigen which includes the Company's majority-owned subsidiary, Triple-Gene LLC, and its collaborations with Fibrocell (Note 5 ). The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately. The Company has also recast 2019 segment information on the same basis as the current presentation. Information by reportable segment was as follows: Three Months Ended March 31, 2020 PGEN Therapeutics ActoBio MBP Titan Trans Ova Human Biotherapeutics All Other Total Revenues from external customers $ 160 $ 198 $ — $ 16,785 $ 10,363 $ 2,292 $ 29,798 Intersegment revenues 2,103 — 7 109 — 281 2,500 Total segment revenues $ 2,263 $ 198 $ 7 $ 16,894 $ 10,363 $ 2,573 $ 32,298 Segment Adjusted EBITDA $ (6,919 ) $ (1,990 ) $ (8,764 ) $ (1,199 ) $ (1,338 ) $ 492 $ (19,718 ) Three Months Ended March 31, 2019 PGEN Therapeutics ActoBio MBP Titan Trans Ova Human Biotherapeutics All Other Total Revenues from external customers $ 1,181 $ 401 $ 1,481 $ 14,934 $ 383 $ 4,097 $ 22,477 Intersegment revenues 2,365 443 — 273 — 13 3,094 Total segment revenues $ 3,546 $ 844 $ 1,481 $ 15,207 $ 383 $ 4,110 $ 25,571 Segment Adjusted EBITDA $ (7,369 ) $ (2,438 ) $ (8,026 ) $ (2,226 ) $ (223 ) $ (1,238 ) $ (21,520 ) The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Three Months Ended 2020 2019 Total segment revenues from reportable segments $ 29,725 $ 21,461 Other revenues, including from other operating segments 3,214 4,218 Elimination of intersegment revenues (3,101 ) (3,094 ) Total consolidated revenues $ 29,838 $ 22,585 The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Three Months Ended 2020 2019 Segment Adjusted EBITDA for reportable segments $ (20,210 ) $ (20,282 ) All Other Segment Adjusted EBITDA 492 (1,238 ) Remove cash paid for capital expenditures and investments in affiliates 2,741 3,512 Add recognition of previously deferred revenue associated with upfront and milestone payments 12,473 4,612 Other expenses: Interest expense (4,592 ) (4,305 ) Depreciation and amortization (4,810 ) (5,344 ) Stock-based compensation expense (5,718 ) (8,248 ) Adjustment related to bonuses paid in equity awards 2,833 — Equity in net loss of affiliates (351 ) (748 ) Other 9 — Unallocated corporate costs (10,182 ) (18,022 ) Eliminations (2,587 ) (2,850 ) Consolidated net loss from continuing operations before income taxes $ (29,902 ) $ (52,913 ) As of March 31, 2020 and December 31, 2019 , the Company had $6,182 and $6,724 , respectively, of long-lived assets in foreign countries from continuing operations. The Company recognized revenues from continuing operations derived in foreign countries totaling $241 and $532 for the three months ended March 31, 2020 and 2019 , respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of March 31, 2020 and results of operations and cash flows for the interim periods ended March 31, 2020 and 2019 . The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2020 , or for any other future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 .
Consolidation	The accompanying condensed consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Equity Method Investments	Equity Method Investments
Variable Interest Entities	As of March 31, 2020 and December 31, 2019
Accounts Receivable	Effective January 1, 2020, the Company applies Financial Accounting Standards Board ("FASB") Accounting Standard Update ("ASU") 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including trade receivables. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance. The Company is exposed to credit losses primarily through sales of products and services by Trans Ova in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted. Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.
Segment Information	The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. As of March 31, 2020 , the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) MBP Titan, (iv) Trans Ova, and (v) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, MBP Titan, and Trans Ova. See Note 19
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis and there was no material impact to the accompanying consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This ASU is intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Accounts Receivable, Allowance for Credit Loss	The following table shows the activity in the allowance for credit losses for the three months ended March 31, 2020 : Balance at December 31, 2019 $ 7,513 Charged to operating expenses 523 Write offs of accounts receivable, net of recoveries 1 Balance at March 31, 2020 $ 8,037

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows: TS Biotechnology Sale EnviroFlight Sale Total Assets Cash and cash equivalents $ 2,223 $ — $ 2,223 Other current assets 9,698 — 9,698 Property, plant and equipment, net 51,975 — 51,975 Intangible assets, net 20,891 4,383 25,274 Investments in affiliates — 7,817 7,817 Right-of-use assets 13,622 — 13,622 Other noncurrent assets 212 — 212 Total assets held for sale $ 98,621 $ 12,200 $ 110,821 Liabilities Deferred revenue, current (1) $ 8,723 $ — $ 8,723 Operating lease liabilities, current 2,459 — 2,459 Other current liabilities 3,058 41 3,099 Deferred revenue, net of current portion (2) 19,410 — 19,410 Operating lease liabilities, net of current portion 12,623 — 12,623 Other long-term liabilities 1,019 — 1,019 Total liabilities held for sale $ 47,292 $ 41 $ 47,333 (1) Includes deferred revenue, current, from related parties of $1,243 . (2) Includes deferred revenue, net of current portion, from related parties of $6,836 . The following tables present the financial results of discontinued operations: Three Months Ended March 31, 2020 TS Biotechnology Sale EnviroFlight Sale Total Revenue (1) $ 1,294 $ — $ 1,294 Operating expenses 896 — 896 Operating income 398 — 398 Gain on sale of discontinued operations 633 39 672 Loss on release of cumulative foreign currency translation adjustment (26,957 ) — (26,957 ) Other expense, net (129 ) — (129 ) Equity in net loss of affiliates — (38 ) (38 ) Loss before income taxes (26,055 ) 1 (26,054 ) Income tax expense (2 ) — (2 ) Loss from discontinued operations $ (26,057 ) $ 1 $ (26,056 ) (1) Includes revenue recognized from related parties of $436 . Three Months Ended March 31, 2019 TS Biotechnology Sale EnviroFlight Sale Total Revenue (1) $ 750 $ — $ 750 Operating expenses 9,119 118 9,237 Operating loss (8,369 ) (118 ) (8,487 ) Other expense, net (422 ) — (422 ) Equity in net loss of affiliates — (892 ) (892 ) Loss before income taxes (8,791 ) (1,010 ) (9,801 ) Income tax benefit 565 — 565 Loss from discontinued operations $ (8,226 ) $ (1,010 ) $ (9,236 ) (1) Includes the reversal of revenue recognized from related parties of $978 . The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying condensed consolidated statements of cash flows. Three Months Ended 2020 2019 Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization $ — $ 1,233 Unrealized and realized depreciation on equity securities and preferred stock, net 106 379 Equity in net loss of EnviroFlight 38 892 Stock-based compensation expense (1,346 ) 806 Deferred income taxes — (481 ) Gain on sale of discontinued operations (672 ) — Loss on release of cumulative foreign currency translation adjustment 26,957 — Cash flows from investing activities Purchases of property, plant and equipment (382 ) (7,700 ) Also see Note 13 below. Equity Method Investments The Company accounted for its investment in EnviroFlight using the equity method of accounting. Summarized financial data for equity method investments included in discontinued operations are shown in the following tables for the periods in which the Company held the equity method investments. December 31, 2019 Current assets $ 703 Noncurrent assets 30,549 Total assets 31,252 Current liabilities 2,352 Non-current liabilities 88 Total liabilities 2,440 Net assets $ 28,812 Three Months Ended 2020 2019 Revenues $ 16 $ 94 Operating expenses 92 1,881 Operating loss (76 ) (1,787 ) Other, net — 4 Net loss $ (76 ) $ (1,783 )

Collaboration and Licensing R_2

Collaboration and Licensing Revenue (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summarized Collaboration and Licensing Revenues	The following table summarizes the amounts recorded as revenue from continuing operations in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2020 and 2019 . Three Months Ended 2020 2019 ZIOPHARM Oncology, Inc. $ 100 $ 1,166 Oragenics, Inc. 198 201 Intrexon Energy Partners, LLC — 977 Intrexon Energy Partners II, LLC — 504 Fibrocell Science, Inc. 10,363 383 Harvest start-up entities (1) — 2,723 Other 60 17 Total $ 10,721 $ 5,971 (1) For the three months ended March 31, 2019 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.
Summary of Deferred Revenue	Deferred revenue consisted of the following: March 31, December 31, Collaboration and licensing agreements $ 40,209 $ 50,593 Prepaid product and service revenues 3,461 2,805 Other 348 435 Total $ 44,018 $ 53,833 Current portion of deferred revenue $ 11,141 $ 5,697 Long-term portion of deferred revenue 32,877 48,136 Total $ 44,018 $ 53,833
Summary of Deferred Revenue by Collaborator	The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of March 31, 2020 and December 31, 2019 , as well as the estimated remaining performance period as of March 31, 2020 . Average Remaining Performance Period (Years) March 31, December 31, Oragenics, Inc. 4.2 $ 2,823 $ 2,864 Intrexon Energy Partners, LLC 4.0 8,362 8,362 Intrexon Energy Partners II, LLC 4.7 12,843 12,843 Fibrocell Science, Inc. 1.0 7,359 17,697 Harvest start-up entities (1) 4.9 6,993 6,993 Other 2.5 1,829 1,834 Total $ 40,209 $ 50,593 (1) As of March 31, 2020 and December 31, 2019 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Short-term Investments (Tables)

Short-term Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments	The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of March 31, 2020 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 110,489 $ 579 $ — $ 111,068 Certificates of deposit 264 — — 264 Total $ 110,753 $ 579 $ — $ 111,332 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2019 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 8,989 $ 7 $ — $ 8,996 Certificates of deposit 264 — — 264 Total $ 9,253 $ 7 $ — $ 9,260

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of March 31, 2020 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, Assets U.S. government debt securities $ — $ 111,068 $ — $ 111,068 Other — 264 — 264 Total $ — $ 111,332 $ — $ 111,332 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2019 : Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 8,996 $ — $ 8,996 Other — 264 — 264 Total $ — $ 9,260 $ — $ 9,260

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: March 31, December 31, Supplies, embryos and other production materials $ 2,191 $ 2,282 Work in process 3,965 3,702 Livestock 6,601 7,553 Feed 1,879 2,560 Total inventory $ 14,636 $ 16,097

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following: March 31, December 31, Land and land improvements $ 9,814 $ 9,814 Buildings and building improvements 11,765 11,765 Furniture and fixtures 1,385 1,315 Equipment 52,498 54,448 Leasehold improvements 12,839 12,821 Breeding stock 5,576 5,191 Computer hardware and software 9,426 9,434 Construction and other assets in progress 5,382 5,313 108,685 110,101 Less: Accumulated depreciation and amortization (49,058 ) (49,132 ) Property, plant and equipment, net $ 59,627 $ 60,969

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended March 31, 2020 are as follows: Balance at December 31, 2019 $ 63,754 Foreign currency translation adjustments (51 ) Balance at March 31, 2020 $ 63,703
Schedule of Intangible Assets	Intangible assets consist of the following as of March 31, 2020 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 89,363 $ (27,793 ) $ 61,570 Customer relationships 10,700 (8,658 ) 2,042 Trademarks 5,900 (4,023 ) 1,877 Total $ 105,963 $ (40,474 ) $ 65,489 Intangible assets consist of the following as of December 31, 2019 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 90,659 $ (26,619 ) $ 64,040 Customer relationships 10,700 (8,440 ) 2,260 Trademarks 5,900 (3,854 ) 2,046 Total $ 107,259 $ (38,913 ) $ 68,346

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	Long-term debt consists of the following: March 31, December 31, Convertible debt $ 216,523 $ 213,771 Notes payable 3,976 4,089 Other 117 131 Long-term debt 220,616 217,991 Less current portion 31,886 31,670 Long-term debt, less current portion $ 188,730 $ 186,321
Schedule of Components of Interest Expense	The components of interest expense related to the Convertible Notes were as follows: Three Months Ended 2020 2019 Cash interest expense $ 1,750 $ 1,750 Non-cash interest expense 2,517 2,213 Total interest expense $ 4,267 $ 3,963
Schedule of Future Maturities of Long-Term Debt	Future maturities of long-term debt are as follows: 2020 $ 31,805 2021 25,329 2022 343 2023 200,356 2024 371 2025 385 Thereafter 1,950 Total $ 260,539

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows: March 31, December 31, Unrealized gain on investments $ 579 $ 7 Loss on foreign currency translation adjustments (1,933 ) (27,475 ) Total accumulated other comprehensive loss $ (1,354 ) $ (27,468 )

Share-Based Payments (Tables)

Share-Based Payments (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Costs	Stock-based compensation costs included in the condensed consolidated statements of operations are presented below: Three Months Ended 2020 2019 Cost of products $ 4 $ 8 Cost of services 29 65 Research and development 589 1,341 Selling, general and administrative 5,096 6,834 Discontinued operations (1,346 ) 806 Total $ 4,372 $ 9,054
Schedule of Stock Option Activity	Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2019 9,022,282 $ 21.94 6.10 Granted 5,280,592 10.44 Forfeited (641,750 ) (18.13 ) Expired (594,177 ) (25.40 ) Balances at March 31, 2020 13,066,947 17.33 7.01 Exercisable at March 31, 2020 6,905,395 21.86 4.92
Schedule of Restricted Stock Unit Activity	RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2019 1,781,982 $ 8.71 1.24 Granted 2,952,917 3.07 Vested (1,016,775 ) (6.16 ) Forfeited (328,978 ) (8.45 ) Balances at March 31, 2020 3,389,146 4.59 0.69

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Components of Lease Costs	Other information related to operating leases in continuing operations was as follows: March 31, December 31, Weighted average remaining lease term (years) 5.02 5.24 Weighted average discount rate 10.97 % 10.96 % Three Months Ended 2020 2019 Supplemental Cash Flows Information Cash paid for operating lease liabilities $ 1,877 $ 1,835 Operating lease right-of-use assets added in exchange for new lease liabilities 25 — The components of lease costs from continuing operations were as follows: Three Months Ended 2020 2019 Operating lease costs $ 1,760 $ 1,841 Short-term lease costs 437 479 Variable lease costs 493 514 Lease costs $ 2,690 $ 2,834
Maturities of Lease Liabilities	As of March 31, 2020 , maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows: 2020 $ 5,137 2021 7,407 2022 6,957 2023 5,799 2024 5,700 2025 3,410 Thereafter 817 Total 35,227 Present value adjustment (8,505 ) Total $ 26,722 Current portion of operating lease liabilities $ 4,308 Long-term portion of operating lease liabilities 22,414 Total $ 26,722

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss per Share	The following table presents the computation of basic and diluted net loss per share: Three Months Ended 2020 2019 Historical net loss per share: Numerator: Net loss from continuing operations attributable to Precigen $ (29,942 ) $ (51,473 ) Net loss from discontinued operations attributable to Precigen (26,056 ) (9,236 ) Net loss attributable to Precigen $ (55,998 ) $ (60,709 ) Denominator: Weighted average shares outstanding, basic and diluted 160,338,743 152,948,058 Net loss per share: Net loss from continuing operations attributable to Precigen per share, basic and diluted $ (0.19 ) $ (0.34 ) Net loss from discontinued operations attributable to Precigen per share, basic and diluted (0.16 ) (0.06 ) Net loss attributable to Precigen per share, basic and diluted $ (0.35 ) $ (0.40 )
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share	The following potentially dilutive securities as of March 31, 2020 and 2019 , have been excluded from the above computations of diluted weighted average shares outstanding for the three months then ended as they would have been anti-dilutive: March 31, 2020 2019 Convertible debt 31,614,643 22,025,046 Options 13,066,947 11,705,841 Restricted stock units 3,389,146 2,288,017 Warrants 133,264 133,264 Total 48,204,000 36,152,168

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Information by Reportable Segment	Information by reportable segment was as follows: Three Months Ended March 31, 2020 PGEN Therapeutics ActoBio MBP Titan Trans Ova Human Biotherapeutics All Other Total Revenues from external customers $ 160 $ 198 $ — $ 16,785 $ 10,363 $ 2,292 $ 29,798 Intersegment revenues 2,103 — 7 109 — 281 2,500 Total segment revenues $ 2,263 $ 198 $ 7 $ 16,894 $ 10,363 $ 2,573 $ 32,298 Segment Adjusted EBITDA $ (6,919 ) $ (1,990 ) $ (8,764 ) $ (1,199 ) $ (1,338 ) $ 492 $ (19,718 ) Three Months Ended March 31, 2019 PGEN Therapeutics ActoBio MBP Titan Trans Ova Human Biotherapeutics All Other Total Revenues from external customers $ 1,181 $ 401 $ 1,481 $ 14,934 $ 383 $ 4,097 $ 22,477 Intersegment revenues 2,365 443 — 273 — 13 3,094 Total segment revenues $ 3,546 $ 844 $ 1,481 $ 15,207 $ 383 $ 4,110 $ 25,571 Segment Adjusted EBITDA $ (7,369 ) $ (2,438 ) $ (8,026 ) $ (2,226 ) $ (223 ) $ (1,238 ) $ (21,520 )
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The table below reconciles total segment revenues from reportable segments to total consolidated revenues: Three Months Ended 2020 2019 Total segment revenues from reportable segments $ 29,725 $ 21,461 Other revenues, including from other operating segments 3,214 4,218 Elimination of intersegment revenues (3,101 ) (3,094 ) Total consolidated revenues $ 29,838 $ 22,585 The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes: Three Months Ended 2020 2019 Segment Adjusted EBITDA for reportable segments $ (20,210 ) $ (20,282 ) All Other Segment Adjusted EBITDA 492 (1,238 ) Remove cash paid for capital expenditures and investments in affiliates 2,741 3,512 Add recognition of previously deferred revenue associated with upfront and milestone payments 12,473 4,612 Other expenses: Interest expense (4,592 ) (4,305 ) Depreciation and amortization (4,810 ) (5,344 ) Stock-based compensation expense (5,718 ) (8,248 ) Adjustment related to bonuses paid in equity awards 2,833 — Equity in net loss of affiliates (351 ) (748 ) Other 9 — Unallocated corporate costs (10,182 ) (18,022 ) Eliminations (2,587 ) (2,850 ) Consolidated net loss from continuing operations before income taxes $ (29,902 ) $ (52,913 )

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Liquidity and Going Concern - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Net loss attributable to Precigen	$ (55,998)	$ (60,709)
Accumulated deficit	$ (1,708,867)		$ (1,652,869)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Maximum risk of loss related to the identified VIEs	$ 1,108	$ 1,461

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Accounts Receivable - Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of period	$ 7,513
Charged to operating expenses	523	$ 64
Write offs of accounts receivable, net of recoveries	1
Balance at end of period	$ 8,037

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Segment Information (Details)	3 Months Ended
	Mar. 31, 2019segment
Accounting Policies [Abstract]
Number of reportable segments	1,000

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Jan. 31, 2020	Jan. 02, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	$ 26,957	$ 0
Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	26,957
TS Biotechnology Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration			$ 53,000
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	26,957
TS Biotechnology Sale | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Prior period adjustment, loss	26,572
EnviroFlight Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration				$ 12,200
Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations	$ 0

Discontinued Operations - Carry

Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	$ 0	$ 2,223
Discontinued Operations, Held-for-sale
Assets
Cash and cash equivalents		2,223
Other current assets		9,698
Property, plant and equipment, net		51,975
Intangible assets, net		25,274
Investments in affiliates		7,817
Right-of-use assets		13,622
Other noncurrent assets		212
Total assets held for sale		110,821
Liabilities
Deferred revenue, current		8,723
Operating lease liabilities, current		2,459
Other current liabilities		3,099
Deferred revenue, net of current portion		19,410
Operating lease liabilities, net of current portion		12,623
Other long-term liabilities		1,019
Total liabilities held for sale		47,333
TS Biotechnology Sale | Discontinued Operations, Held-for-sale
Assets
Cash and cash equivalents		2,223
Other current assets		9,698
Property, plant and equipment, net		51,975
Intangible assets, net		20,891
Right-of-use assets		13,622
Other noncurrent assets		212
Total assets held for sale		98,621
Liabilities
Deferred revenue, current		8,723
Operating lease liabilities, current		2,459
Other current liabilities		3,058
Deferred revenue, net of current portion		19,410
Operating lease liabilities, net of current portion		12,623
Other long-term liabilities		1,019
Total liabilities held for sale		47,292
EnviroFlight Sale | Discontinued Operations, Held-for-sale
Assets
Cash and cash equivalents		0
Other current assets		0
Property, plant and equipment, net		0
Intangible assets, net		4,383
Investments in affiliates		7,817
Right-of-use assets		0
Other noncurrent assets		0
Total assets held for sale		12,200
Liabilities
Deferred revenue, current		0
Operating lease liabilities, current		0
Other current liabilities		41
Deferred revenue, net of current portion		0
Operating lease liabilities, net of current portion		0
Other long-term liabilities		0
Total liabilities held for sale		41
Related Parties, Aggregated | TS Biotechnology Sale | Discontinued Operations, Held-for-sale
Liabilities
Deferred revenue, current		1,243
Deferred revenue, net of current portion		$ 6,836

Discontinued Operations - Summa

Discontinued Operations - Summary of Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on release of cumulative foreign currency translation adjustment	$ (26,957)	$ 0
Loss from discontinued operations	(26,056)	(9,236)
Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	1,294
Operating expenses	896
Operating income (loss)	398
Gain on sale of discontinued operations	672
Loss on release of cumulative foreign currency translation adjustment	(26,957)
Other expense, net	(129)
Equity in net loss of affiliates	(38)
Loss before income taxes	(26,054)
Income tax benefit (expense)	(2)
Loss from discontinued operations	(26,056)
Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue		750
Operating expenses		9,237
Operating income (loss)		(8,487)
Other expense, net		(422)
Equity in net loss of affiliates		(892)
Loss before income taxes		(9,801)
Income tax benefit (expense)		565
Loss from discontinued operations		(9,236)
TS Biotechnology Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	1,294
Operating expenses	896
Operating income (loss)	398
Gain on sale of discontinued operations	633
Loss on release of cumulative foreign currency translation adjustment	(26,957)
Other expense, net	(129)
Loss before income taxes	(26,055)
Income tax benefit (expense)	(2)
Loss from discontinued operations	(26,057)
TS Biotechnology Sale | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue		750
Operating expenses		9,119
Operating income (loss)		(8,369)
Other expense, net		(422)
Loss before income taxes		(8,791)
Income tax benefit (expense)		565
Loss from discontinued operations		(8,226)
EnviroFlight Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	0
Operating expenses	0
Operating income (loss)	0
Gain on sale of discontinued operations	39
Loss on release of cumulative foreign currency translation adjustment	0
Other expense, net	0
Equity in net loss of affiliates	(38)
Loss before income taxes	1
Income tax benefit (expense)	0
Loss from discontinued operations	1
EnviroFlight Sale | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue		0
Operating expenses		118
Operating income (loss)		(118)
Other expense, net		0
Equity in net loss of affiliates		(892)
Loss before income taxes		(1,010)
Income tax benefit (expense)		0
Loss from discontinued operations		(1,010)
Related Parties, Aggregated | TS Biotechnology Sale | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 436
Related Parties, Aggregated | TS Biotechnology Sale | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue		$ (978)

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$ 4,810	$ 6,577
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	106	(70)
Equity in net loss of EnviroFlight	389	1,640
Stock-based compensation expense	4,372	9,054
Deferred income taxes	0	(508)
Gain on sale of discontinued operations	(672)	0
Loss on release of cumulative foreign currency translation adjustment	26,957	0
Cash flows from investing activities
Purchases of property, plant and equipment	(3,152)	(11,523)
TS Biotechnology Holdings LLC and EnviroFlight LLC | Discontinued Operations, Held-for-sale
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	0	1,233
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	106	379
Equity in net loss of EnviroFlight	38	892
Stock-based compensation expense	(1,346)	806
Deferred income taxes	0	(481)
Gain on sale of discontinued operations	(672)	0
Loss on release of cumulative foreign currency translation adjustment	26,957	0
Cash flows from investing activities
Purchases of property, plant and equipment	$ (382)	$ (7,700)

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details) - TS Biotechnology Holdings LLC and EnviroFlight LLC - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets			$ 703
Noncurrent assets			30,549
Total assets			31,252
Current liabilities			2,352
Non-current liabilities			88
Total liabilities			2,440
Net assets			$ 28,812
Revenues	$ 16	$ 94
Operating expenses	92	1,881
Operating loss	(76)	(1,787)
Other, net	0	4
Net loss	$ (76)	$ (1,783)

Investments in Joint Ventures -

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2014USD ($)	Mar. 31, 2020USD ($)board_seat	Dec. 31, 2019USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 1,108,000	$ 1,461,000
Intrexon Energy Partners, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Maximum additional capital contribution committed	$ 25,000,000
Additional capital contributions committed, remaining commitment		$ 4,225,000
Total number of seats on the joint venture's governing board | board_seat		5
Total number of seats on the joint venture's governing board, internally selected | board_seat		2
Total number of seats on the joint venture's governing board, externally selected | board_seat		3
Intrexon Energy Partners, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (422,000)	$ (423,000)
Intrexon Energy Partners, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Capital contributions	$ 25,000,000
Maximum additional capital contribution committed	25,000,000
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 25,000,000

Investments in Joint Ventures_2

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015USD ($)board_seat	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 1,108,000	$ 1,461,000
Intrexon Energy Partners II, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Maximum additional capital contribution committed	$ 10,000,000
Additional capital contributions committed, remaining commitment		10,000,000
Total number of seats on the joint venture's governing board | board_seat	5
Total number of seats on the joint venture's governing board, internally selected | board_seat	1
Total number of seats on the joint venture's governing board, externally selected | board_seat	4
Intrexon Energy Partners II, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (433,000)	$ (435,000)
Intrexon Energy Partners II, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Capital contributions	$ 18,000,000
Maximum additional capital contribution committed	10,000,000
Intrexon Energy Partners II, LLC | All Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	4,000,000
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 18,000,000

Collaboration and Licensing R_3

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenue (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		$ 29,838	$ 22,585
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		10,721	5,971
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		100	1,166
Oragenics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		198	201
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		0	977
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		0	504
Fibrocell Science, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		10,363	383
Harvest start-up entities | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	[1]	0	2,723
Other | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		$ 60	$ 17
[1]	For the three months ended March 31, 2019 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Collaboration and Licensing R_4

Collaboration and Licensing Revenue - Fibrocell Science Collaboration (Details) $ in Thousands	1 Months Ended
	Feb. 29, 2020USD ($)
Collaboration and licensing agreements | Fibrocell Science, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 10,000

Collaboration and Licensing R_5

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 44,018	$ 53,833
Current portion of deferred revenue	11,141	5,697
Long-term portion of deferred revenue	32,877	48,136
Collaboration and licensing agreements
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	40,209	50,593
Prepaid product and service revenues
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	3,461	2,805
Other
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 348	$ 435

Collaboration and Licensing R_6

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands		Mar. 31, 2020	Dec. 31, 2019
Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			$ 50,593
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 40,209
Oragenics, Inc. | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			2,864
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 2 months 12 days
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 2,823
Intrexon Energy Partners, LLC | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			8,362
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 8,362
Intrexon Energy Partners II, LLC | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			12,843
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 8 months 12 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 12,843
Fibrocell Science, Inc. | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			17,697
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		1 year
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 7,359
Harvest start-up entities | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	[1]		6,993
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	[1]	4 years 10 months 24 days
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	[1]	$ 6,993
Other | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			$ 1,834
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		2 years 6 months
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 | Upfront and milestone payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 1,829
[1]	As of March 31, 2020 and December 31, 2019 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Collaboration and Licensing R_7

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details) - Upfront and milestone payments $ in Thousands	Dec. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 50,593
Oragenics, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	2,864
Intrexon Energy Partners, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	8,362
Intrexon Energy Partners II, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	12,843
Fibrocell Science, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	17,697
Harvest start-up entities
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	6,993	[1]
Other
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 1,834
[1]	As of March 31, 2020 and December 31, 2019 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Short-term Investments - Summar

Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 110,753	$ 9,253
Gross Unrealized Gains	579	7
Gross Unrealized Losses	0	0
Aggregate Fair Value	111,332	9,260
U.S. government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	110,489	8,989
Gross Unrealized Gains	579	7
Gross Unrealized Losses	0	0
Aggregate Fair Value	111,068	8,996
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	264	264
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 264	$ 264

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 111,332	$ 9,260
Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	111,332	9,260
Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	111,068	8,996
U.S. government debt securities | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	111,068	8,996
U.S. government debt securities | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Other
Assets
Fair value of financial assets measured at fair value on a recurring basis	264	264
Other | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Other | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	264	264
Other | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Jul. 31, 2018
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis	$ 585,000	$ 585,000
Changes in fair value of Level 3 liabilities	$ 0
3.5% Convertible Notes Due 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, interest rate, stated percentage	3.50%		3.50%
Fair value of convertible debt	$ 96,000,000	126,000,000
Carrying value of convertible debt	$ 160,077,000	$ 157,560,000	$ 143,723,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Inventory	$ 14,636	$ 16,097
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	2,191	2,282
Work in process
Inventory [Line Items]
Inventory	3,965	3,702
Livestock
Inventory [Line Items]
Inventory	6,601	7,553
Feed
Inventory [Line Items]
Inventory	$ 1,879	$ 2,560

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 9,814	$ 9,814
Buildings and building improvements	11,765	11,765
Furniture and fixtures	1,385	1,315
Equipment	52,498	54,448
Leasehold improvements	12,839	12,821
Breeding stock	5,576	5,191
Computer hardware and software	9,426	9,434
Construction and other assets in progress	5,382	5,313
Property, plant and equipment, gross	108,685	110,101
Less: Accumulated depreciation and amortization	(49,058)	(49,132)
Property, plant and equipment, net	$ 59,627	$ 60,969

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,931	$ 3,178

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill
Beginning balance	$ 63,754
Foreign currency translation adjustments	(51)
Ending balance	$ 63,703

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill accumulated impairment losses	$ 43,643		$ 43,643
Amortization expense	$ 1,879	$ 2,166

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	$ (40,474)	$ (38,913)
Intangible Assets
Gross Carrying Amount	105,963	107,259
Net	65,489	68,346
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	89,363	90,659
Accumulated Amortization	(27,793)	(26,619)
Net	61,570	64,040
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	10,700	10,700
Accumulated Amortization	(8,658)	(8,440)
Net	2,042	2,260
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	5,900	5,900
Accumulated Amortization	(4,023)	(3,854)
Net	$ 1,877	$ 2,046

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit	3 Months Ended
	Mar. 31, 2020USD ($)
Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of credit facility, interest rate at period end	4.54%
Line of credit facility, outstanding balance	$ 1,205,000
Line of credit facility, current borrowing capacity	$ 3,725,000
Trans Ova Genetics, LC | First National Bank of Omaha | Minimum
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%
Trans Ova Genetics, LC | First National Bank of Omaha | London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Line of credit facility, basis spread on variable rate	2.95%
Exemplar Genetics, LLC | American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	5.50%
Line of credit facility, outstanding balance	$ 0

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Schedule of Long-Term Debt Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long-term debt	$ 220,616	$ 217,991
Less current portion	31,886	31,670
Long-term debt, less current portion	188,730	186,321
Convertible debt
Debt Instrument [Line Items]
Long-term debt	216,523	213,771
Notes payable
Debt Instrument [Line Items]
Long-term debt	3,976	4,089
Other
Debt Instrument [Line Items]
Long-term debt	$ 117	$ 131

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended		3 Months Ended
	Dec. 31, 2018	Jul. 31, 2018USD ($)day$ / shares	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2018USD ($)
Debt Instrument [Line Items]
Proceeds from long-term debt, net of issuance costs			$ 0	$ 376,000
Deferred income taxes			0	508,000
Accrued interest			1,750,000
Long-term debt			220,616,000		$ 217,991,000
Convertible debt
Debt Instrument [Line Items]
Long-term debt			216,523,000		213,771,000
Notes payable
Debt Instrument [Line Items]
Long-term debt			3,976,000		4,089,000
Precigen ActoBio Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage						3.00%
Interest expense			235,000	$ 225,000
Long-term debt			$ 31,446,000
Trans Ova Genetics, LC | Notes payable | American State Bank
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			3.95%
Long-term debt			$ 3,973,000
Debt instrument, periodic payment			39,000
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio Inc.
Debt Instrument [Line Items]
Aggregate principal amount						$ 30,000,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount		$ 200,000,000	$ 200,000,000
Proceeds from long-term debt, net of issuance costs		193,958,000
Debt issuance costs		$ 6,042,000
Debt instrument, interest rate, stated percentage		3.50%	3.50%
Conversion rate		58.6622
Principal amount used in conversion		$ 1,000
Conversion price (in usd per share) | $ / shares		$ 17.05
Debt instrument redemption price, percentage		100.00%
Carrying value of convertible debt		$ 143,723,000	$ 160,077,000		157,560,000
Equity component of convertible debt, net of issuance costs and deferred taxes		50,235,000
Deferred income taxes		$ 13,367,000
Effective interest rate on convertible notes			11.02%
Convertible notes, unamortized discount and issuance costs			$ 39,923,000
3.5% Convertible Notes Due 2023 | Minimum
Debt Instrument [Line Items]
Common stock price trading days | day		20
Common stock price consecutive trading days | day		30
Percentage of common share price over conversion price for conversion		130.00%
3.5% Convertible Notes Due 2023 | Maximum
Debt Instrument [Line Items]
Common stock price trading days | day		5
Common stock price consecutive trading days | day		5
Debt instrument redemption price, percentage		98.00%
Merck Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount					$ 25,000,000
Conversion rate upon IPO	0.90
Interest rate applicable to IPO conversion event					0.05

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Schedule of Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Cash interest expense	$ 1,750	$ 1,750
Non-cash interest expense	2,517	2,213
Total interest expense	$ 4,267	$ 3,963

Lines of Credit and Long-Term_7

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Mar. 31, 2020USD ($)
Debt Disclosure [Abstract]
2020	$ 31,805
2021	25,329
2022	343
2023	200,356
2024	371
2025	385
Thereafter	1,950
Total	$ 260,539

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Loss Carryforwards [Line Items]
Deferred income taxes	$ 0	$ (508,000)
Deferred tax liabilities	2,785,000
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Taxable loss	(79,300,000)	(91,600,000)
Current income tax expense (benefit)		0
Operating loss carryforwards	647,500,000
Deferred tax assets, capital loss carryforwards	199,700,000
Research and development tax credits	10,000,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	71,900,000
Generated After 2017
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	394,800,000
Continuing Operations
Operating Loss Carryforwards [Line Items]
Deferred income taxes	0	(27,000)
Continuing Operations | Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Current income tax expense (benefit)	$ 40,000	$ 14,000

Shareholders' Equity - Issuance

Shareholders' Equity - Issuances of Precigen Common Stock (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Mar. 31, 2019
Class of Stock [Line Items]
Shares and warrants issued in public and private offerings, net of issuance costs		$ 6,611
TS Biotechnology Holdings LLC
Class of Stock [Line Items]
Shares issued (in shares)	5,972,696
Shares and warrants issued in public and private offerings, net of issuance costs	$ 35,000

Shareholders' Equity - Share Le

Shareholders' Equity - Share Lending Agreement (Details)	1 Months Ended
	Jul. 31, 2018$ / sharesshares
Equity [Abstract]
Borrowed shares, number issued (in shares) | shares	7,479,431
Share lending agreement, length of time for shares to be returned upon termination	5 years
Borrowed shares, public offering price per share (in usd per share) | $ / shares	$ 13.37

Shareholders' Equity - Issuan_2

Shareholders' Equity - Issuances of AquaBounty Common Stock (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2019
Class of Stock [Line Items]
Shares and warrants issued in public and private offerings, net of issuance costs		$ 6,611
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Shares and warrants issued in public and private offerings, net of issuance costs	$ 6,611

Shareholders' Equity - Componen

Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ 87,229	$ 71,711
Unrealized gain on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	579	7
Loss on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	(1,933)	(27,475)
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Precigen shareholders' equity	$ (1,354)	$ (27,468)

Share-Based Payments - Schedule

Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ 4,372	$ 9,054
Cost of products
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	4	8
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	29	65
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	589	1,341
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	5,096	6,834
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ (1,346)	$ 806

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2020	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 930	$ 831
Executive Chairman, former Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly compensation, in the form of equity	$ 200
Lock-up period	3 years
Executive Chairman, former Chief Executive Officer | Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 454	$ 486
Precigen Stock Option Plan 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)				0
Options outstanding (in shares)	244,231
Precigen Stock Option Plan 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	3,301,269
Options outstanding (in shares)	12,052,124
Number of shares authorized for issuance (in shares)	25,000,000
RSUs outstanding (in shares)	2,891,634
Precigen Stock Option Plan 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	2,582,279
Options outstanding (in shares)	770,592
Number of shares authorized for issuance (in shares)	5,000,000
RSUs outstanding (in shares)	497,512
Forecast | Precigen Stock Option Plan 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in shares)			2,000,000

Share-Based Payments - Schedu_2

Share-Based Payments - Schedule of Stock Option Activity (Details) - Precigen Stock Option Plans - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Number of Shares
Balances at beginning of period (in shares)	9,022,282
Granted (in shares)	5,280,592
Forfeited (in shares)	(641,750)
Expired (in shares)	(594,177)
Balances at end of period (in shares)	13,066,947	9,022,282
Exercisable at end of period (in shares)	6,905,395
Weighted Average Exercise Price
Balances at beginning of period (in usd per share)	$ 21.94
Granted (in usd per share)	10.44
Forfeited (in usd per share)	(18.13)
Expired (in usd per share)	(25.40)
Balances at period end (in usd per share)	17.33	$ 21.94
Exercisable, weighted average exercise price, at end of period (in usd per share)	$ 21.86
Weighted Average Remaining Contractual Term (Years)
Balances, weighted average remaining contractual period	7 years 3 days	6 years 1 month 6 days
Exercisable at period end, weighted average remaining contractual period	4 years 11 months 1 day

Share-Based Payments - Schedu_3

Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Number of Restricted Stock Units
Forfeited (in shares)	(328,978)
Weighted Average Grant Date Fair Value
Forfeited (in usd per share)	$ (8.45)
Precigen Stock Option Plans
Number of Restricted Stock Units
Balances at beginning of period (in shares)	1,781,982
Granted (in shares)	2,952,917
Vested (in shares)	(1,016,775)
Balances at end of period (in shares)	3,389,146	1,781,982
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 8.71
Granted (in usd per share)	3.07
Vested (in usd per share)	(6.16)
Balances at end of period (in usd per share)	$ 4.59	$ 8.71
Additional Information
Weighted Average Remaining Contractual Term (Years)	21 days	1 year 2 months 26 days

Operating Leases - Additional I

Operating Leases - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	10 years

Operating Leases - Components o

Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease costs	$ 1,760	$ 1,841
Short-term lease costs	437	479
Variable lease costs	493	514
Lease costs	$ 2,690	$ 2,834

Operating Leases - Maturities o

Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2020	$ 5,137
2021	7,407
2022	6,957
2023	5,799
2024	5,700
2025	3,410
Thereafter	817
Total	35,227
Present value adjustment	(8,505)
Total	26,722
Current portion of lease liabilities	4,308	$ 4,182
Long-term portion of operating lease liabilities	$ 22,414	$ 23,849

Operating Leases - Lease Terms

Operating Leases - Lease Terms and Discount Rates (Details)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Weighted average remaining lease term (years)	5 years 7 days	5 years 2 months 26 days
Weighted average discount rate	10.97%	10.96%

Operating Leases - Other Inform

Operating Leases - Other Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$ 1,877	$ 1,835
Operating lease right-of-use assets added in exchange for new lease liabilities	$ 25	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Contingencies - Additional Information (Details) - Licensing and patent infringement suit	1 Months Ended			4 Months Ended	12 Months Ended	25 Months Ended	37 Months Ended	38 Months Ended	148 Months Ended
	Mar. 31, 2019USD ($)claim	Dec. 31, 2016claim	Apr. 30, 2016USD ($)	May 21, 2022	Dec. 31, 2016USD ($)claim	Jan. 04, 2022	Mar. 31, 2019USD ($)claim	Mar. 31, 2019USD ($)claim	Apr. 30, 2016USD ($)	Feb. 28, 2019claim
Loss Contingencies [Line Items]
Damages awarded to Trans Ova			$ 528,000
Litigation settlement, aggregate royalty and license payment								$ 5,801,000	$ 3,170,000
Royalty payments not yet deposited			2,759,000						$ 2,759,000
Litigation settlement expense					$ 4,228,000
Back royalties								$ 1,000,000
XY, LLC
Loss Contingencies [Line Items]
Damages awarded against Trans Ova			$ 6,066,000
Litigation settlement, ongoing royalty percentage	18.75%		12.50%
Enhancement rate on products utilizing reverse sorting			2.00%
Cumulative payments for royalties and licenses	$ 6.25		$ 5				$ 6.25
Weighted blended royalty rate	12.63%
Claims dismissed | claim		9					10
Total claims | claim		12
Non-patent counts, number | claim		5
Patent counts, number | claim		4
Claims pending resolution | claim	2	2			2		2	2		1
Forecast | XY, LLC
Loss Contingencies [Line Items]
Weighted blended royalty rate						3.93%
Royalty rate				5.00%

Related Party Transactions - A

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Nov. 30, 2015	Mar. 31, 2020	Mar. 31, 2019
Related Party Transaction [Line Items]
Common stock calculation period				30 days
Related party payables		$ 51		$ 139
Proceeds from sales of equity securities				0	$ 418
Other receivables		4,978		351
Third Security, LLC
Related Party Transaction [Line Items]
Expense for services				38	17
Sublease rental income				$ 22	22
Third Security, LLC | Common Stock
Related Party Transaction [Line Items]
Expense for services			$ 800
Related party payables					$ 2,078
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Proceeds from sales of equity securities		1,280
Proceeds from convertible notes receivable and investment in preferred stock	$ 3,311
Other receivables		$ 3,311
Third Security, LLC | Executive Chairman
Related Party Transaction [Line Items]
Ownership interest				100.00%

Net Loss per Share - Computatio

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Numerator:
Net loss from continuing operations attributable to Precigen	$ (29,942)	$ (51,473)
Net loss from discontinued operations attributable to Precigen	(26,056)	(9,236)
Net loss attributable to Precigen	$ (55,998)	$ (60,709)
Denominator:
Weighted average shares outstanding, basic and diluted (in shares)	160,338,743	152,948,058
Net Loss Per Share [Abstract]
Net loss from continuing operations attributable to Precigen per share, basic and diluted (in dollars per share)	$ (0.19)	$ (0.34)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in dollars per share)	(0.16)	(0.06)
Net loss attributable to Precigen per share, basic and diluted (in dollars per share)	$ (0.35)	$ (0.40)

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	48,204,000	36,152,168
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	31,614,643	22,025,046
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	13,066,947	11,705,841
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	3,389,146	2,288,017
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	133,264	133,264

Segments - Information by Repor

Segments - Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues from external customers	$ 29,838	$ 22,585
Segment Adjusted EBITDA	(19,718)	(21,520)
PGEN Therapeutics
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(6,919)	(7,369)
ActoBio
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(1,990)	(2,438)
MBP Titan
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(8,764)	(8,026)
Trans Ova
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(1,199)	(2,226)
Human Biotherapeutics
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(1,338)	(223)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	492	(1,238)
Operating segments
Segment Reporting Information [Line Items]
Revenues from external customers	29,798	22,477
Revenues	32,298	25,571
Operating segments | PGEN Therapeutics
Segment Reporting Information [Line Items]
Revenues from external customers	160	1,181
Revenues	2,263	3,546
Operating segments | ActoBio
Segment Reporting Information [Line Items]
Revenues from external customers	198	401
Revenues	198	844
Operating segments | MBP Titan
Segment Reporting Information [Line Items]
Revenues from external customers	0	1,481
Revenues	7	1,481
Operating segments | Trans Ova
Segment Reporting Information [Line Items]
Revenues from external customers	16,785	14,934
Revenues	16,894	15,207
Operating segments | Human Biotherapeutics
Segment Reporting Information [Line Items]
Revenues from external customers	10,363	383
Revenues	10,363	383
Operating segments | All Other
Segment Reporting Information [Line Items]
Revenues from external customers	2,292	4,097
Revenues	2,573	4,110
Intersegment revenues
Segment Reporting Information [Line Items]
Revenues	2,500	3,094
Intersegment revenues | PGEN Therapeutics
Segment Reporting Information [Line Items]
Revenues	2,103	2,365
Intersegment revenues | ActoBio
Segment Reporting Information [Line Items]
Revenues	0	443
Intersegment revenues | MBP Titan
Segment Reporting Information [Line Items]
Revenues	7	0
Intersegment revenues | Trans Ova
Segment Reporting Information [Line Items]
Revenues	109	273
Intersegment revenues | Human Biotherapeutics
Segment Reporting Information [Line Items]
Revenues	0	0
Intersegment revenues | All Other
Segment Reporting Information [Line Items]
Revenues	$ 281	$ 13

Segments - Reconciliation of Re

Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	$ 29,838	$ 22,585
Other revenues, including from other operating segments
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	3,214	4,218
Elimination of intersegment revenues
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	(3,101)	(3,094)
Total segment revenues from reportable segments
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	$ 29,725	$ 21,461

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	$ (19,718)	$ (21,520)
Other expenses:
Depreciation and amortization	(4,810)	(6,577)
Stock-based compensation expense	(4,372)	(9,054)
Equity in net loss of affiliates	(389)	(1,640)
Other	(239)	(235)
Loss before income taxes	(29,902)	(52,913)
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures and investments in affiliates	2,741	3,512
Corporate And Reconciling Items
Other expenses:
Interest expense	(4,592)	(4,305)
Depreciation and amortization	(4,810)	(5,344)
Stock-based compensation expense	(5,718)	(8,248)
Adjustment related to bonuses paid in equity awards	2,833	0
Equity in net loss of affiliates	(351)	(748)
Other	9	0
Unallocated corporate costs
Other expenses:
Loss before income taxes	(10,182)	(18,022)
Eliminations
Other expenses:
Loss before income taxes	(2,587)	(2,850)
Segment Adjusted EBITDA for reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(20,210)	(20,282)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	492	(1,238)
Upfront and milestone payments | Operating segments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	$ 12,473	$ 4,612

Segments - Additional Informati

Segments - Additional Information (Details) - Non-US - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Long-lived assets	$ 6,182		$ 6,724
Revenues	$ 241	$ 532

Uncategorized Items - pgen-2020

Label	Element	Value
Restricted Cash and Cash Equivalents, Noncurrent	us-gaap_RestrictedCashAndCashEquivalentsNoncurrent	$ 418,000
Restricted Cash and Cash Equivalents, Noncurrent	us-gaap_RestrictedCashAndCashEquivalentsNoncurrent	$ 410,000